Scientists launch new attack against AIDS

EU-funded researchers have developed a new defence against infection from the AIDS (acquired immune deficiency syndrome) virus. The pioneering method involves creating a protective shield that restricts the virus from making contact with a susceptible host cell and penetrating the immune system. Published in the journal Chemistry & Biology, the results pave the way for future pharmaceutical drugs that could combat the disease in its early stages.

The three-year breakthrough study was led by Dr Félix Goñi of the Consejo Superior de Investigaciones Científicas (CSIC) in Spain, together with several CSIC departments and Spanish institutes specialising in chemistry and molecular biology.

Their novel approach is based on the regulation of cell membrane fluidity in order to prevent the occurrence of 'membrane fusion', where contact is established between the cell membranes and the membrane of the AIDS virus.

As the protective, fragile layer of the cytoplasm, the membrane of a cell has a similar structure to that of the AIDS virus membrane. Fusion occurs when both membranes make contact, thus producing an orifice that acts as an entry point for the virus. At this stage, the virus attaches to a cell receptor and begins to spread.

The objective for Dr Goñi and his team was to make the membrane structure stronger and more rigid so as to prevent fusion from taking place altogether, and to avoid the subsequent viral escalation.

Dr Goñi explained that in order for the orifice to be created, the membranes must be fluid and mobile. To counter this, the team discovered a procedure that makes the cell membranes tougher and less yielding.

"This [method] could well give rise to a new pharmaceutical drug, which makes the membranes more rigid and impede the entrance of the AIDS virus. Instead of the membrane being flexible, a kind of armour is established which makes the cell impenetrable," Dr Goñi pointed out.

Almost all existing methods to treat the AIDS virus focus on the need to stop the spread of the virus when it is already inside the first cell. An exception is Enfurvitide, a treatment that aims to stop the virus from entering the host cell but is based on a completely different principle to the one developed by Dr Goñi and his team.

Beyond the AIDS virus, the strategy also has the potential to be applied to the flu virus and other viruses with membrane.

The research was supported by two EU projects totalling EUR 21.89 million: CHAIN (Collaborative HIV and anti-HIV drug resistance network), and INNOCHEM (Innovative chemokine-based therapeutic strategies for autoimmunity and chronic inflammation). These projects were funded under the Health Theme of the Seventh Framework Programme (FP7) and the 'Life sciences, genomics and biotechnology for health' Thematic Area of the Sixth Framework Programme (FP6) respectively.

For more information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...